CLVLF
Price
$7.43
Change
-$0.60 (-7.47%)
Updated
Oct 17 closing price
Capitalization
377.61M
IONS
Price
$73.09
Change
+$0.02 (+0.03%)
Updated
Oct 17 closing price
Capitalization
11.65B
11 days until earnings call
Interact to see
Advertisement

CLVLF vs IONS

Header iconCLVLF vs IONS Comparison
Open Charts CLVLF vs IONSBanner chart's image
Clinuvel Pharmaceuticals
Price$7.43
Change-$0.60 (-7.47%)
Volume$126
Capitalization377.61M
Ionis Pharmaceuticals
Price$73.09
Change+$0.02 (+0.03%)
Volume$1.31M
Capitalization11.65B
CLVLF vs IONS Comparison Chart in %
CLVLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLVLF vs. IONS commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLVLF is a Hold and IONS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (CLVLF: $7.43 vs. IONS: $73.09)
Brand notoriety: CLVLF and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLVLF: 18% vs. IONS: 50%
Market capitalization -- CLVLF: $377.61M vs. IONS: $11.65B
CLVLF [@Biotechnology] is valued at $377.61M. IONS’s [@Biotechnology] market capitalization is $11.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLVLF’s FA Score shows that 1 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • CLVLF’s FA Score: 1 green, 4 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, both CLVLF and IONS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLVLF’s TA Score shows that 4 TA indicator(s) are bullish while IONS’s TA Score has 3 bullish TA indicator(s).

  • CLVLF’s TA Score: 4 bullish, 5 bearish.
  • IONS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CLVLF is a better buy in the short-term than IONS.

Price Growth

CLVLF (@Biotechnology) experienced а -13.60% price change this week, while IONS (@Biotechnology) price change was +4.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

IONS is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($11.6B) has a higher market cap than CLVLF($378M). IONS YTD gains are higher at: 109.067 vs. CLVLF (-12.071). CLVLF has higher annual earnings (EBITDA): 57.2M vs. IONS (-170.69M). IONS has more cash in the bank: 2.29B vs. CLVLF (224M). CLVLF has less debt than IONS: CLVLF (529K) vs IONS (1.42B). IONS has higher revenues than CLVLF: IONS (944M) vs CLVLF (95M).
CLVLFIONSCLVLF / IONS
Capitalization378M11.6B3%
EBITDA57.2M-170.69M-34%
Gain YTD-12.071109.067-11%
P/E Ratio15.90N/A-
Revenue95M944M10%
Total Cash224M2.29B10%
Total Debt529K1.42B0%
FUNDAMENTALS RATINGS
CLVLF vs IONS: Fundamental Ratings
CLVLF
IONS
OUTLOOK RATING
1..100
8924
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10061
SMR RATING
1..100
5198
PRICE GROWTH RATING
1..100
5436
P/E GROWTH RATING
1..100
7362
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLVLF's Valuation (3) in the null industry is significantly better than the same rating for IONS (100) in the Biotechnology industry. This means that CLVLF’s stock grew significantly faster than IONS’s over the last 12 months.

IONS's Profit vs Risk Rating (61) in the Biotechnology industry is somewhat better than the same rating for CLVLF (100) in the null industry. This means that IONS’s stock grew somewhat faster than CLVLF’s over the last 12 months.

CLVLF's SMR Rating (51) in the null industry is somewhat better than the same rating for IONS (98) in the Biotechnology industry. This means that CLVLF’s stock grew somewhat faster than IONS’s over the last 12 months.

IONS's Price Growth Rating (36) in the Biotechnology industry is in the same range as CLVLF (54) in the null industry. This means that IONS’s stock grew similarly to CLVLF’s over the last 12 months.

IONS's P/E Growth Rating (62) in the Biotechnology industry is in the same range as CLVLF (73) in the null industry. This means that IONS’s stock grew similarly to CLVLF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLVLFIONS
RSI
ODDS (%)
Bullish Trend 1 day ago
57%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
59%
Bearish Trend 1 day ago
73%
Momentum
ODDS (%)
Bearish Trend 1 day ago
57%
Bullish Trend 1 day ago
64%
MACD
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
56%
Bullish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
52%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 20 days ago
50%
Bullish Trend 1 day ago
65%
Declines
ODDS (%)
N/A
Bearish Trend 12 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 1 day ago
69%
Aroon
ODDS (%)
Bearish Trend 1 day ago
45%
Bullish Trend 1 day ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
CLVLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DECZ40.710.17
+0.42%
TrueShares Structured Outcome Dec ETF
STXM28.140.02
+0.06%
Strive Mid-Cap ETF
BHYB54.49N/A
N/A
Xtrackers USD High Yld BB-B ex Fin ETF
GBXC26.52N/A
N/A
Goldman Sachs U.S. Lg Cp Buffr 3 ETF
NUW14.17-0.04
-0.28%
Nuveen AMT-Free Municipal Value Fund

CLVLF and

Correlation & Price change

A.I.dvisor tells us that CLVLF and IONS have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLVLF and IONS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLVLF
1D Price
Change %
CLVLF100%
-7.53%
IONS - CLVLF
24%
Poorly correlated
+0.03%
PXXLF - CLVLF
23%
Poorly correlated
N/A
NICXF - CLVLF
22%
Poorly correlated
N/A
RVMD - CLVLF
21%
Poorly correlated
+8.90%
MDWD - CLVLF
21%
Poorly correlated
-3.47%
More

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with CYTK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
+0.03%
CYTK - IONS
64%
Loosely correlated
-0.88%
MLYS - IONS
51%
Loosely correlated
+1.37%
ARWR - IONS
51%
Loosely correlated
-5.54%
MNKD - IONS
48%
Loosely correlated
+2.24%
RARE - IONS
48%
Loosely correlated
-3.93%
More